Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financial Analysts Roundtable Part II: Changes On Capitol Hill, FDA’s Risk Threshold And The Future Of The Cholesterol Market

Executive Summary

The following excerpts are from a conversation "The Pink Sheet" had with three large cap pharmaceutical analysts, Prudential's Tim Anderson, Goldman Sachs' Jim Kelly and Morgan Stanley's Jami Rubin, concerning the outlook for the drug industry in 2007. 1Kelly and 2Rubin provided "The Pink Sheet" with extensive disclosure statements, which can be accessed by visiting 3www.ThePinkSheet.com. The 4first part of the series, which covered Medicare Part D, big pharma diversification, and the outlook for M&A, appeared in the Feb. 5 issue of "The Pink Sheet."

You may also be interested in...



FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance

FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency

FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance

FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency

Teva Retains Simvastatin Share As New Entrants Struggle To Meet Demand

Generic companies may find it difficult to assess how much supply to produce when a large product loses 180-day exclusivity, comments by Teva Pharmaceuticals USA CEO William Marth suggest

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel